Coronary Artery Disease: Clinical Outcomes and Treatment
Clinical Outcomes and Prognosis
Patients with stable coronary artery disease face annual mortality rates of 1.2–2.4%, with cardiac death occurring in 0.6–1.4% and non-fatal myocardial infarction in 0.6–2.7% annually, though prognosis varies dramatically based on disease severity—from 0.63% annual mortality in those with non-obstructive plaques to 3.8% in very high-risk patients with diabetes, peripheral arterial disease, or prior MI. 1
Prognostic Factors That Worsen Outcomes
- Reduced left ventricular ejection fraction and heart failure significantly increase mortality risk 1
- Greater number of diseased vessels and more proximal coronary stenoses predict worse outcomes 1
- Extensive myocardial ischemia (>10% of LV mass) identifies high-risk patients 2
- Impaired functional capacity, older age, and severe angina symptoms correlate with increased mortality 1
- Conventional risk factors—hypertension, hypercholesterolemia, diabetes, obesity, smoking—accelerate disease progression and worsen prognosis 1
- Elevated resting heart rate indicates worse prognosis 1
Immediate Pharmacological Treatment
Antiplatelet Therapy (Mandatory Foundation)
Aspirin 75–100 mg daily must be started immediately in all patients with coronary artery disease to reduce myocardial infarction and death. 2, 3, 4
- Clopidogrel 75 mg daily is the only acceptable alternative when aspirin is absolutely contraindicated 1, 2, 4
- Dual antiplatelet therapy (aspirin plus clopidogrel) is required for 6 months after coronary stent implantation 2, 4
- Add a proton pump inhibitor in all patients on antiplatelet therapy who have high gastrointestinal bleeding risk 3, 4
- Never use dipyridamole—it worsens exercise-induced myocardial ischemia 1, 2
Lipid-Lowering Therapy (Mandatory for All)
High-intensity statin therapy must be initiated immediately in every patient with coronary artery disease, targeting LDL-cholesterol <55 mg/dL (1.4 mmol/L) with at least 50% reduction from baseline. 2, 3, 4
- Add ezetimibe if maximum tolerated statin dose fails to achieve LDL goals 2, 3, 4
- Add a PCSK9 inhibitor (evolocumab or alirocumab) for very high-risk patients not reaching goals on statin plus ezetimibe 2, 3, 4
- Add bempedoic acid as an additional option when LDL remains above target 2
ACE Inhibitors (Mandatory in Most Patients)
ACE inhibitors must be prescribed to all patients with coronary artery disease, particularly when hypertension, diabetes, heart failure, or left ventricular dysfunction coexist. 1, 2, 3, 4
- ARBs are acceptable only if ACE inhibitor is not tolerated 2, 3, 4
- Target office systolic blood pressure 120–130 mmHg (130–140 mmHg if age >65 years) 2
- Never combine ACE inhibitors with ARBs—this increases harm without benefit 2, 3, 4
Beta-Blockers (First-Line for Symptoms and Mortality)
Beta-blockers are first-line therapy for heart rate control and angina relief, and are mandatory in patients with prior myocardial infarction to reduce subsequent cardiac events and mortality. 1, 2, 3, 4
- Diabetes is not a contraindication—diabetic patients benefit equally or more than non-diabetics 1, 2
- Beta-blockers reduce morbidity and mortality in post-MI patients 1
Short-Acting Nitrates (Universal Prescription)
Sublingual nitroglycerin must be prescribed to all patients for immediate relief of effort-induced angina, with symptom resolution expected within 1–5 minutes. 2, 4
Additional Therapies for Specific Populations
SGLT2 inhibitors with proven cardiovascular benefit are required for all patients with type 2 diabetes and coronary artery disease, regardless of HbA1c level. 2, 4
GLP-1 receptor agonist semaglutide should be considered in non-diabetic patients with coronary artery disease and BMI >27 kg/m² to reduce cardiovascular mortality, MI, and stroke. 2
Low-dose colchicine 0.5 mg daily may be used to reduce myocardial infarction, stroke, and need for revascularization in patients with atherosclerotic coronary disease. 2
Symptom Management When Beta-Blockers Are Insufficient
Long-acting calcium-channel blockers are preferred over long-acting nitrates for maintenance therapy because they provide sustained 24-hour anti-ischemic effects. 1, 2
- Add a long-acting calcium-channel blocker or long-acting nitrate when beta-blocker monotherapy fails to control symptoms 2
- Calcium-channel blockers are appropriate when beta-blockers are contraindicated or poorly tolerated 1, 2
- Never use immediate-release or short-acting dihydropyridine calcium antagonists—they increase adverse cardiac events 1, 2
Lifestyle Modifications (Mandatory at Every Visit)
Exercise-based cardiac rehabilitation is fundamental and significantly reduces cardiovascular mortality and morbidity while improving risk factor control. 2, 3
- Aerobic physical activity 150–300 minutes per week of moderate intensity 3
- Mediterranean, DASH, or AHA diet with saturated fat <7% of total calories 3
- Mandatory tobacco cessation with quantitative assessment at every visit 2, 3, 4
- Weight management targeting obesity reduction 3
- Annual influenza vaccination, especially in elderly patients 2
- Psychological interventions to address depression symptoms 2
Indications for Revascularization
Mandatory Revascularization for Survival Benefit
In patients with LVEF >35% and functionally significant left-main stenosis, coronary revascularization is mandatory to improve survival. 2
In patients with LVEF >35% and functionally significant three-vessel disease, revascularization is mandatory to improve long-term survival and lower cardiovascular mortality and spontaneous MI. 2
In patients with LVEF >35% and functionally significant single- or two-vessel disease involving the proximal left anterior descending artery, revascularization is mandatory to reduce long-term cardiovascular mortality and spontaneous MI. 2
Revascularization for Symptom Relief
When angina persists despite guideline-directed medical therapy (aspirin, statin, ACE inhibitor, beta-blocker, and optimal antianginal drugs), revascularization of functionally significant obstructive disease is required to relieve symptoms. 2, 3, 4
- Severe angina refractory to maximal medical therapy warrants urgent invasive coronary angiography 2, 3
Special Considerations for Reduced LVEF
For patients with LVEF ≤35%, a multidisciplinary Heart Team must evaluate coronary anatomy, the relationship between disease and ventricular dysfunction, comorbidities, life expectancy, risk-benefit balance, and patient preferences before deciding between revascularization and medical therapy alone. 2
In surgically eligible patients with multivessel disease and LVEF ≤35%, coronary artery bypass grafting (CABG) is recommended over medical therapy alone to improve long-term survival. 2
Choice of Revascularization Strategy
CABG vs. PCI Decision-Making
For patients at low surgical risk with significant left-main coronary stenosis, CABG is preferred over PCI owing to lower rates of spontaneous MI and repeat revascularization. 2
When left-main disease is of low anatomical complexity (SYNTAX score ≤22) and PCI can achieve completeness of revascularization comparable to CABG, PCI may be offered as an alternative because of lower invasiveness and non-inferior survival. 2
In complex multivessel disease, a Heart Team discussion—including interventional cardiology, cardiac surgery, and non-interventional cardiology representatives—is mandatory to select the optimal treatment strategy. 2
Procedural Guidance
Intracoronary imaging (intravascular ultrasound or optical coherence tomography) is mandatory when performing PCI on anatomically complex lesions, particularly left-main stem, true bifurcations, and long lesions. 2
Intracoronary pressure measurement (fractional flow reserve, instantaneous wave-free ratio, or quantitative flow ratio) is mandatory to guide lesion selection for intervention in patients with multivessel disease. 2, 3
Calculate the SYNTAX score to assess anatomical complexity of multivessel obstructive disease. 2
Calculate the STS (Society of Thoracic Surgeons) score to estimate in-hospital morbidity and 30-day mortality after CABG. 2
Follow-Up and Monitoring
Regular cardiovascular healthcare visits every 3–6 months initially to reassess risk status, lifestyle modifications, adherence to risk factor targets, and development of new comorbidities. 3, 4
- Lipid profile assessment 4–12 weeks after initiating statin therapy to evaluate response 3
- Review patient response to medical therapies at 2–4 weeks after drug initiation 2
- Repeat stress imaging or invasive coronary angiography with functional testing in the presence of worsening symptoms and/or increased risk status 3
- Periodic resting ECG in asymptomatic diabetic patients for detection of conduction abnormalities, atrial fibrillation, and silent MI 4
Critical Pitfalls to Avoid
- Do not use ticagrelor or prasugrel as part of triple antithrombotic therapy with aspirin and oral anticoagulation 3, 4
- Do not combine ACE inhibitors with ARBs 2, 3, 4
- Do not neglect proton pump inhibitor in patients on antiplatelet therapy at high GI bleeding risk 3, 4
- Do not use coronary CTA as a routine follow-up test for patients with established CAD 2, 3
- Do not perform invasive coronary angiography solely for risk stratification without clinical indication 2, 3
- Do not withhold beta-blockers in diabetic patients 1, 2
- Do not use immediate-release dihydropyridine calcium antagonists 1, 2
- Do not use dipyridamole 1, 2